Abstracts Archive - Page 2225 of 2425 - ACR Meeting Abstracts

Abstract Number: 372 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk In Intensively Treated Rheumatoid Arthritis: Comparison To An Osteoarthritis Population. First Prospective Analysis Of The ACT-CVD Cohort
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality. This association is thought to be due to the chronic inflammatory disease…
Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Michael Cocker¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (
Abstract Number: 374 • 2013 ACR/ARHP Annual Meeting
Effect Of Age At Menopause In Women With Early Rheumatoid Arthritis
Lauren Wong¹, Wei-Ti Huang², Juan Xiong³, Gilles Boire⁴, Boulos Haraoui⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Carol A. Hitchon⁸, Diane Tin⁹, Edward Keystone¹⁰ and Vivian P. Bykerk¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁶Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) preferentially affects women and studies suggest that various hormonal and reproductive factors may affect disease onset and severity. This study assessed…
Abstract Number: 375 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation Contributes To Depression In Patients With Rheumatoid Arthritis
Mary Margaretten¹, Laura Trupin², Patricia P. Katz², Gabriela Schmajuk², Jinoos Yazdany², Chris Tonner², Jennifer Barton² and Edward H. Yelin³, ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Prior research suggests that systemic inflammation contributes to the pathogenesis of depression, but longitudinal studies in patients with rheumatoid arthritis (RA) are lacking. Comorbid…
Abstract Number: 376 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients
Johanna Bengtsson¹, Pierre Geborek², Tore Saxne³, Martin Englund⁴, Ingemar F. Petersson⁴, Jan-Åke Nilsson⁵, Göran Jönsson⁶ and Meliha C. Kapetanovic⁷, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Lund Universoty, Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, ⁷Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
The risk of pneumococcal infections after immunisation with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patientsBackground/Purpose: The purpose was to examine the risk of…
Abstract Number: 377 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Stroke In Patients With Rheumatoid Arthritis
Anja Strangfeld¹, Yvette Meißner², Adrian Richter³, Matthias Schneider⁴, Hans Peter Tony⁵, Kerstin Gerhold⁶, Angela Zink⁷ and Joachim Listing³, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center Berlin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Department of Endocrinology, Diabetes and Rheumatology, University of Duesseldorf, Duesseldorf, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁶Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of stroke. This event is associated with considerable sequelae and might result in death or…
Abstract Number: 378 • 2013 ACR/ARHP Annual Meeting
HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up
Lie Dai, An Qi Liang, Ying Qian Mo, Jian Da Ma, Le Feng Chen, Dong Hui Zheng and Lang Jing Zhu, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Approximate 7.2% Chinese were infected with hepatitis B virus (HBV), and the prevalence of concurrent HBV carriers in Chinese rheumatoid arthritis (RA) patients was…
Abstract Number: 379 • 2013 ACR/ARHP Annual Meeting
Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts
Elena Nikiphorou¹, Lewis Carpenter², Josh Dixey³, Peter Williams⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young⁸, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁴Rheumatology, Medway Maritime Hospital, Gillingham, United Kingdom, ⁵Rheumatology Dept, St George's Hospital, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: The risk of osteoporotic fracture is known to be high in RA. Yet less is known about RA related predictive factors for this…
Abstract Number: 357 • 2013 ACR/ARHP Annual Meeting
Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis
Jose Dionisio Castillo-Ortiz¹ and Cesar Ramos-Remus², ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico
Background/Purpose: Consanguineous relatives of patients with RA are at a higher risk to develop RA. It is also known that specific antibodies including CCP and…
Abstract Number: 340 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis
Philip S. Helliwell¹, Philip Mease², Eustratios Bananis³, Heather Jones⁴, Annette Szumski³ and Lisa Marshall⁴, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Collegeville, PA
Background/Purpose: Most randomized control trials (RCTs) for psoriatic arthritis (PsA) include patients with asymmetric oligoarthritis (AO) and polyarthritis (PA). There are limited data from RCTs…
Abstract Number: 341 • 2013 ACR/ARHP Annual Meeting
Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
Arthur Kavanaugh¹, Iain B. McInnes², Philip J. Mease³, Gerald G. Krueger⁴, Dafna D. Gladman⁵, Stephen Xu⁶, Linda Tang⁷ and Katrien van Beneden⁸, ¹University of California, San Diego, La Jolla, CA, ²Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁴School of Medicine, University of Utah, Salt Lake City, UT, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Janssen Research & Development, LLC., Horsham, PA, ⁸Janssen Biologics Europe, Leiden, Netherlands
Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: Results from 5 years of the long term extension of a randomized, placebo-controlled,…
Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Julio C. B. Moraes¹, Carla G.S. Saad¹, Ana Cristina Ribeiro², Claudia G Schainberg³, Celio R. Gonçalves², Percival D Sampaio-Barros¹ and Eloisa Bonfá², ¹Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…
Abstract Number: 343 • 2013 ACR/ARHP Annual Meeting
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Elisabeth Lie¹, Karen M. Fagerli¹, Erik Rødevand², Synnøve Kalstad³, Knut Mikkelsen⁴, Ada Wierød⁵, Désirée van der Heijde⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ³Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, ⁴Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital Drammen, Drammen, Norway, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Methotrexate (MTX), sulfasalazine (SSZ) and leflunomide (LEF) are recommended treatments for PsA patients with active peripheral arthritis. In the publication of a recent negative…
Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Muhammad Haroon¹, Phil Gallagher² and Oliver FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…
Abstract Number: 345 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Proton Rahman¹, Denis Choquette², William G. Bensen³, Majed M. Khraishi⁴, Isabelle Fortin⁵, Andrew Chow⁶, Maqbool K. Sheriff⁷, Julie Vaillancourt⁸, John S. Sampalis⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: To determine the point prevalence of peri-articular manifestations (PAMs) in psoriatic arthritis (PsA) patients treated with anti-TNF in a real-world, Canadian, routine clinical practice…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].